A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients-Reference-Cited by-同舟云学术

A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients

Published:2020-05-22 Issue:8 Volume:76 Page:1059-1074
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Phillips-Chavez Caitlin^ORCID,Watson Michael,Coward Jermaine,Schloss Janet^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00228-020-02874-4.pdf

Reference89 articles.

1. Cancer Australia. Gynaecological cancer statistics | Gynaecological cancers [Internet]. 2019 [cited 2019 Jun 23]. Available from: https://gynaecological-cancer.canceraustralia.gov.au/statistics

2. The World Ovarian Cancer Coalition. THE WORLD OVARIAN CANCER COALITION ATLAS GLOBAL TRENDS IN INCIDENCE, MORTALITY AND SURVIVAL [Internet]. 2018 [cited 2019 Jun 23]. Available from: https://worldovariancancercoalition.org/wp-content/uploads/2018/10/THE-WORLD-OVARIAN-CANCER-COALITION-ATLAS-2018.pdf

3. Koukoura O, Spandidos DA, Daponte A, Sifakis S (2014) DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review). Mol Med Rep 10(1):3–9 [cited 2018 Apr 12] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24821107

4. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer epidemiology and risk factors. Lancet 374:1371–1382 [cited 2018 Apr 25] Available from: https://ac-els-cdn-com.ezproxy.endeavour.edu.au/S0140673609613386/1-s2.0-S0140673609613386-main.pdf?_tid=f2835517-bfce-4c7c-9485-a51847e13492&acdnat=1524641109_7eff38fc2b115db1fdcf927850752e74

5. Assis J, Pereira C, Nogueira A, Pereira D, Carreira R, Medeiros R (2017) Systematic or Meta-analysis Studies Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis. Cancer Treat Rev 61:35–52 [cited 2018 Mar 5] Available from: https://ac-els-cdn-com.ezproxy.endeavour.edu.au/S0305737217301573/1-s2.0-S0305737217301573-main.pdf?_tid=f9d726e8-f268-461b-843e-b58f1e4ac5f1&acdnat=1520236476_95a61e584d1650ad85e98bd84968cfd5

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing wound healing and overcoming cisplatin resistance in ovarian cancer;International Wound Journal;2023-12-29

2. Quantitative biophysical metrics for rapid evaluation of ovarian cancer metastatic potential;Molecular Biology of the Cell;2022-05-15

3. Monensin suppresses cell proliferation and invasion in ovarian cancer by enhancing MEK1 SUMOylation;Experimental and Therapeutic Medicine;2021-09-30

4. Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results;Cancers;2021-06-26

5. LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer;Journal of Ovarian Research;2021-05-15